Drugs / RR001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06861452 | Jun 2025 → Jul 2026 overdue | pancreatic adenocarcinoma | EIR Biotherapies s.r.l. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06861452 ↗ |
| Action | Deplete | “These cells are derived from adipose tissue and are genetically modified to deliver a potent anti-cancer death ligand normally produced by the body with the role to kill tumoral cells.” NCT06861452 ↗ |
| Modality | Cell therapy | “RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer.” NCT06861452 ↗ |
| Route | Other | “intra-tumoral administration of RR001” NCT06861452 ↗ |